CONSUMER NEWS    RECALLS    COMPLAINT FORM    SCAM ALERTS  


Complain about a product or service

Small Claims Guide | Class Actions | Lemon Law | FAQ | Resources | Newsletters | Spanish
Automotive    Education    Electronics    Family    Finance    Health    Homeowners    Shopping    Travel   
NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

Diabetes Drugs to Get 'Black Box' Warnings

Some popular drugs increase risk of heart failure





August 16, 2007

Diabetes
Studies Find Link Between Diabetes and Alzheimer's
Avandia Maker Failed To Report Required Data
Prediabetes: What You Should Know
Study: Large-Breasted Women More Diabetes-Prone
U.S. Diet Dishes Up Diabetes
Weight-Loss Surgery Seen Beneficial to Diabetics
Lack of Deep Sleep May Increase Diabetes Risk
Study: Avandia May Do More Harm than Good
FDA Orders New Warning For Avandia
U.S. Kidney Disease on the Rise
Fish Oil May Fight Diabetes
Avandia vs. Actos: A Doctor's Advice
Avandia Linked to 42% Greater Risk of Heart Attack
Soft Drink Sweetener Linked to Diabetes in Kids
Diabetes Drugs to Get 'Black Box' Warnings
FDA Rejects Advice to Pull Avandia From Market
FDA Advised to Pull Avandia From Market
Avandia, Other Diabetes Drugs Increase Risk of Heart Failure
Dairy Products May Protect Against Metabolic Syndrome
Portion-Control Dishes May Help Obese Diabetics
FDA Issues Safety Alert on Diabetes Drug Avandia
Stem Cell Treatment May "Cure" Diabetes
Diabetes Risk May Be In The Genes
Holiday Gluttony Can Spell Disaster for Undiagnosed Diabetics
Malaria Drug May Fight Common Cause of Diabetes, Heart Disease
Feds Attack Fake Diabetes Cures
FDA Approves New Treatment for Diabetes
Feds Warn Of Counterfeit Diabetes Tests
Study: Weightlifting Helps Overweight Teens Avoid Diabetes
Researchers Say They Can Reverse Type 1 Diabetes
Study: Obesity Major Factor in Diabetes Epidemic
Too Much, Too Little Sleep Linked To Diabetes In Men
Procedure Cures Some Diabetic Mice
Ethnicity Skews Diabetes' Effect on Heart
Pig Cells May Be Useful in Diabetes Treatment
Protein Triggers Fat-Saturated Cell Death
FDA Approves Diabetes Inhaler Exubera
FDA Panel Greenlights Diabetes Inhaler
Breastfeeding May Decrease Diabetes Risk
Low-Fat Dairy Products May Lower Diabetes Risk in Men
Scientists Find Diabetes "Switch"
New Diabetes Treatment Approved
Knowledge of Diabetes Doesn't Always Affect Outcomes
Moderate Exercise Helpful to Diabetes-Prone Women
Life Expectancy Increases; Diabetes Epidemic Worsens

Manufacturers of certain drugs approved to treat Type 2 diabetes have agreed to add a stronger warning on the risk of heart failure, a condition that occurs when the heart does not adequately pump blood.

The information will be included in the form of a “boxed” warning -- the U.S. Food and Drug Administration’s strongest warning.

The upgraded warning emphasizes that the drugs may cause or worsen heart failure in certain patients.

After a review of postmarketing adverse event reports, FDA determined that an updated label with a boxed warning on the risks of heart failure was needed for the entire thiazolidinedione class of antidiabetic drugs.

This class includes Avandia (rosiglitazone), Actos (pioglitazone) Avandaryl (rosiglitazone and glimepiride), Avandamet (rosiglitazone and metformin), and Duetact (pioglitazone and glimepride).

The drugs are used in conjunction with diet and exercise, to improve blood sugar control in adults with type 2 (non-insulin-dependent) diabetes. FDA had asked the drug’s manufacturers, GlaxoSmithKline and Takeda, to address these concerns.

“Under FDA’s postmarketing surveillance program, we carefully monitor new safety information for marketed drugs and take appropriate action when necessary to inform patients and health care providers of new information,” said Steven Galson, M.D., M.P.H., director of FDA’s Center for Drug Evaluation and Research.

“This new boxed warning addresses FDA’s concerns that despite the warnings and information already listed in the drug labels, these drugs are still being prescribed to patients without careful monitoring for signs of heart failure.”

FDA’s review of adverse event reports found cases of significant weight gain and edema -- warning signs of heart failure. In some reports, FDA noted, continuation of therapy has been associated with poor outcomes, including death.

The strengthened warning advises health care professionals to observe patients carefully for the signs and symptoms of heart failure, including excessive, rapid weight gain, shortness of breath, and edema after starting drug therapy.

Patients with these symptoms who then develop heart failure should receive appropriate management of the heart failure and use of the drug should be reconsidered. People who have questions should contact their health care providers to discuss alternative treatments.

The warning also states that these drugs should not be used by people with serious or severe heart failure who have marked limits on their activity and who are comfortable only at rest or who are confined to bed or a chair.

FDA is continuing its review of Avandia and possible increased risk of heart attacks.

On July 30, 2007, FDA’s Endocrine and Metabolic Advisory Committee and the Drug Safety and Risk Management Advisory Committee recommended that Avandia continue to be marketed, and further recommended that information be added to the labeling for risk of heart attacks (ischemic risks).



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.


Consumer News

May 17 2008

Recent Recalls & Safety Alerts

READER SERVICES

Print, Email & More

Subscribe

Free consumer newsletters
Sign up now!





Back to the top |

Advertisement


Home | Rogues Gallery | Good Guys | Complaint Form | News | Recalls | Search | Video | FAQ |
Consumer Resources | Small Claims Guide | Lemon Law | Newsletter | Contact Us
Advertise With Us | Testimonials | Newsroom | RSS Feeds | Radio | Job Postings




Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2008 ConsumerAffairs.com Inc.  All Rights Reserved.